摘要:
Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.
摘要:
The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.
摘要:
Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要:
Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要:
Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要:
Disclosed are novel tricyclic compounds of the formula: and the pharmaceutically acceptable salts thereof. Y is C or CH. When Y is C then Z is not present and the optional bond from Y to the C-11 carbon of the tricyclic nucleus is present. When Y is CH then Z is present and Z is H or —OH. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要:
The present invention provides compounds of formula I wherein X and R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.
摘要:
A voltage regulator system for regulating an output voltage of a genset includes a voltage regulator for reducing terminal voltage in response to a reduction in terminal frequency. A plurality of under-frequency roll-off (UFRO) states is provided in the voltage regulator, with each UFRO state being configured to implement a UFRO characteristic. An operational signal indicative of an operating condition of the genset forms the basis for selection of the UFRO characteristic.
摘要:
The invention provides a method of carrying out a Lewis-acid catalysed organic reaction in the presence of a Lewis acid catalyst comprising a metal-organic compound having the following formula: M(HO(CR1R2)z)a(O(CR1R2)z)bY—(CR3R4)χ-Y((CR1R2)zO)c((CR1R2)zOH)d.nR5OH (Formula I) in which: M is a metal atom, preferably titanium, zirconium, hafnium or iron (III) Y is selected from P and N, but Ss very preferably N; each R1, R2, R3 and R4 is independently selected from H, alkyl, aryl, substituted alkyl or substituted aryl, R5 is hydrogen, an alkyl group, a hydroxy-functionalised alkyl group, a polyoxyalkylmoiety, R6O or R7COO where R6 and R7 may each represent H, alkyl, aryl or alkyl-aryl; d and a are each O or 1, b and c are each 1 or 2, b+c=the valency of M, a+b+c+d=4, each z is independently 1, 2, 3 or 4; x represents the least number of C atoms between the Y atoms and is 2 or 3 and n is a number in the range from 0 to 4. The metal-organic compound forms a stable hydrate in water which retains Lewis-acid catalytic properties.
摘要翻译:本发明提供一种在路易斯酸催化剂存在下进行路易斯酸催化的有机反应的方法,该路易斯酸催化剂包含具有下式的金属有机化合物:M(HO(CR 1 R 2)z)a(O(CR 1 R 2)z) bY-(CR3R4)χ-Y((CR1R2)zO)c((CR1R2)zOH)d.nR5OH(式I)其中:M是金属原子,优选钛,锆,铪或铁(III)Y是 选自P和N,但S优选为N; 每个R 1,R 2,R 3和R 4独立地选自H,烷基,芳基,取代的烷基或取代的芳基,R 5是氢,烷基,羟基官能化的烷基,聚氧烷基摩尔,R6O或R7COO,其中R6和R7可以 各自表示H,烷基,芳基或烷基 - 芳基; d和a各自为O或1,b和c各自为1或2,b + c = M的化合价,a + b + c + d = 4,每个z独立地为1,2,3或4; x表示Y原子之间的C原子数最少,为2或3,n为0至4的数。该金属有机化合物在水中形成稳定的水合物,保留路易斯酸催化性能。
摘要:
A method of manufacturing a polyurethane compound comprises mixing together a polyol, a polyisocyanate compound and a catalyst and allowing the mixture to cure to form a polyurethane, and is characterized in that the catalyst is a neutral complex of a metal selected from Ti, Zr, Hf, Al, Fe, Bi or Sn and a multidentate organic ligand having: a) a number of anionic donor sites=x; b) a number of neutral donor sites, capable of forming a co-ordinate bond with the metal, =y; c) where x+y=from 5 to 8; d) x is from 2 to 4; e) the ligand molecule is of a size and conformation to enable each of the anionic donor sites and neutral donor sites to form a bond with the same metal atom.